A Systematic Review of the Cost Effectiveness of Herpes Zoster Vaccination

Abstract

Model input parameters such as age at vaccination, vaccine costs, HZ incidence, PHN length and duration of vaccine efficacy had a great impact on the estimated cost effectiveness of HZ vaccination. To compare the results of different cost-effectiveness studies of HZ vaccination, uniform methods should be used and the most important input parameters used for the different models should be critically assessed.

Cost-effectiveness of vaccination against herpes zoster

“…These findings are consistent with other reviews summarizing evidence on the cost-effectiveness of HZ vaccination. 15,49 However, compared with the review of Szucz et al, 49 three more studies were included. Moreover, this review contains more specific data on the clinical results found in the studies, the influence of the modeling of vaccine efficacy on cost-effectiveness results and the optimum age of vaccination.…”

“…[34][35][36][37][38][39][40][41][42][43][44][45][46][47] In addition, two studies performed a multiway sensitivity analysis 37,45 and nine studies a probabilistic sensitivity analysis (PSA). 35,[37][38][39][40][41][42][43]46 Quality assessment A review of Szucs et al 49 evaluated the quality of 11 of the included studies using the British Medical Journal (BMJ)'s checklist by Drummond and Jefferson 50 and the "Quality of Health Economic Studies" evaluation tool by Ofman et al 51 Szucs et al 49 concluded that the quality of these studies varied from 'Moderate' 37,38,4337,38,43 to 'Moderate-Good' 35,36,[39][40][41][42]44 . We assessed the three other included studies using the same criteria as Szucs et al 49 used.…”

“…35,[37][38][39][40][41][42][43]46 Quality assessment A review of Szucs et al 49 evaluated the quality of 11 of the included studies using the British Medical Journal (BMJ)'s checklist by Drummond and Jefferson 50 and the "Quality of Health Economic Studies" evaluation tool by Ofman et al 51 Szucs et al 49 concluded that the quality of these studies varied from 'Moderate' 37,38,4337,38,43 to 'Moderate-Good' 35,36,[39][40][41][42]44 . We assessed the three other included studies using the same criteria as Szucs et al 49 used. The study of Bilcke et al 45 was judged as 'Good' and the study of Bresse et al 46 and de Boer et al 47 were evaluated as 'Moderate-Good'.…”

“…Besides efficacy against HZ incidence, most studies included additional efficacy of vaccination toward PHN 35,36,38,39,41,42,46,47,49 or toward the burden of disease (BOI) 35,37,[40][41][42][43][44][45][46] in the base-case scenario. Two studies imposed additional efficacy against PHN in a scenario analysis.…”

Clinical and economic impact of herpes zoster vaccination in elderly in Italy

“…[5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22] Although the mathematical models and the assumptions are different, these studies demonstrate clearly that the HZ vaccination in the elderly population has a favorable economic profile. Vaccination could have a significant impact on HZ disease and, above all, results a very good investment for NHS and Society.…”